Newer blood thinners linked to slower cognitive decline in Alzheimer’s patients

New research indicates that newer oral anticoagulants, known as non‑vitamin K antagonist oral anticoagulants (NOACs), may slow cognitive decline in patients who have both Alzheimer’s disease and atrial fibrillation. The study compared three groups—patients treated with NOACs, those using the traditional blood thinner warfarin, and individuals not receiving any anticoagulant therapy—to assess changes in cognitive performance over time.

Results showed that participants on NOACs experienced a modest but statistically significant reduction in the yearly rate of cognitive deterioration relative to the warfarin and no‑treatment groups. Although the annual difference was small, the cumulative effect could become clinically meaningful over several years. Researchers suggest that the observed benefit may stem from more consistent anticoagulation and fewer microvascular events, but they caution that further trials are needed to confirm the findings and to evaluate long‑term safety.